Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Thyroid Cancer Drugs Market Expected to Grow Between 2025 And 2029?

The market size for drugs used to treat thyroid cancer has seen significant expansion in recent years. Projected growth from $1.17 billion in 2024 to $1.35 billion in 2025 corresponds to a 15.5% compound annual growth rate (CAGR). This notable increase over the historical timeframe can be ascribed to a rise in thyroid cancer cases, advancements in medical investigation, a supportive regulatory landscape, and expanding investments in healthcare.

What Growth Rate Is Anticipated for the Thyroid Cancer Drugs Market in the Coming Years?

The market size of drugs for thyroid cancer is projected to experience swift expansion in the coming few years. The market is anticipated to reach $2.2 billion by 2029, with a compound annual growth rate (CAGR) of 13.0%. The growth during the forecast period can be ascribed to the rising prevalence and elder demographics, precision medicine advancements, upliftment in healthcare infrastructure, and the surge in early detection and awareness. Notable trends for the forecast period encompass personalized medicine, targeted and immunotherapies, clinical experiments and drug pipeline, combination treatments, treatments driven by biomarkers, telemedicine, and remote monitoring.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2601&type=smp

Who Are the Leading Companies in the Thyroid Cancer Drugs Market?

Major companies operating in the thyroid cancer drugs market include Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline plc, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.

What Are the Key Drivers of the Thyroid Cancer Drugs Market?

The thyroid cancer drugs market is being propelled by a rise in thyroid cancer cases, particularly among women. The American Cancer Society, a US-based organization, estimated roughly 43,800 new incidences of thyroid cancer in the United States in 2022. Out of these, women accounted for 31,940 cases and men for 11,860 cases. There were also 2,230 deaths from thyroid cancer, with 1,070 men and 1,160 women succumbing to the disease. Hence, the escalating prevalence of thyroid cancer, particularly in women, fuels the expansion of the thyroid cancer sector.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2601&type=smp

What Are the Key Market Segments in the Thyroid Cancer Drugs Industry?

The thyroid cancer drugs market covered in this report is segmented –

1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types

2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types

3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users

Subsegments:

1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab

2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib

3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib

4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin

5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib

6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab

7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib

8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab

What Are the Latest Trends in the Thyroid Cancer Drugs Market?

The use of combination drugs in thyroid cancer therapy is on the rise due to their enhanced effectiveness and ability to impede cancer progression. These medications blend two or more active pharmaceutical components (APIs) into a single dosage, reducing drug resistance development and halting cancer cell proliferation. For instance, the U.S. Food and Drug Administration (FDA) has sanctioned the use of a combination drug that incorporates dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor for addressing anaplastic thyroid cancer.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

What Are the Key Regional Markets in the Thyroid Cancer Drugs Industry?

North America was the largest region in the thyroid cancer drugs market in 20232. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2601

This Report Delivers Insight On:

1. How big is the thyroid cancer drugs market, and how is it changing globally?

2. Who are the major companies in the thyroid cancer drugs market, and how are they performing?

3. What are the key opportunities and risks in the thyroid cancer drugs market right now?

4. Which products or customer segments are growing the most in the thyroid cancer drugs market?

5. What factors are helping or slowing down the growth of the thyroid cancer drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.